Barsotti J, Benhamou A C, Guerois C, Gratteau B, Guilmot J L, Jolidon C
J Mal Vasc. 1983;8(2):139-42.
The authors observed 9 patients submitted to prophylactic treatment with adequately doses subcutaneous heparin, for orthopaedic or traumatic surgery (chiefly total hip arthroplasty) who presented between the 7 and 9 day after starting heparin therapy, thrombotic complications including recurrent arterial occlusions and venous thrombosis associated with a profound thrombocytopenia, with a maximum platelet count below 30,000 per cubic millimeter. A rapid increase of platelet count after heparin withdrawal is observed, and the profound thrombocytopenia seems to be immune mediated with heparin dependent platelet antibodies, in most of the reported cases. We propose a platelet count for all surgical patients with heparin therapy, and if a thrombocytopenia appears, with a platelet count in the range of: 80,000 clinical inspection and platelet aggregation investigations, and immediate cessation of heparin therapy at 30,000 platelets/mm3.
作者观察了9例接受皮下注射足量肝素进行预防性治疗的患者,这些患者因骨科或创伤手术(主要是全髋关节置换术)接受治疗,在肝素治疗开始后的第7至9天出现血栓并发症,包括复发性动脉闭塞和静脉血栓形成,并伴有严重血小板减少症,血小板计数最高低于每立方毫米30,000。在大多数报道的病例中,停用肝素后血小板计数迅速增加,严重血小板减少症似乎是由肝素依赖性血小板抗体介导的免疫反应。我们建议对所有接受肝素治疗的手术患者进行血小板计数,如果出现血小板减少症,血小板计数在80,000范围内时进行临床检查和血小板聚集研究,血小板计数为30,000/mm³时立即停止肝素治疗。